Establishment and analysis of a novel miRNA prognostic risk model for bladder cancer based on TCGA database

References

• Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, et al. 2013. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 37:219–225.
   PubMed Web of Science ®Google Scholar
• Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. 2020. Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci. 21:1723.
   PubMed Web of Science ®Google Scholar
• Blanca A, Cheng L, Montironi R, Moch H, Massari F, Fiorentino M, Raspollini MR, Scarpelli M, Lopez-Beltran A. 2017. Mirna expression in bladder cancer and their potential role in clinical practice. Curr Drug Metab. 18:712–722.
   PubMed Web of Science ®Google Scholar
• Gong L, Lei Y, Tan X, Dong Y, Luo Z, Zhang D, Han S. 2019. Propranolol selectively inhibits cervical cancer cell growth by suppressing the cGMP/PKG pathway. Biomed Pharmacother. 111:1243–1248.
   PubMed Web of Science ®Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. 2000. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 56:337–344.
   PubMed Web of Science ®Google Scholar
• Inamoto T, Uehara H, Akao Y, Ibuki N, Komura K, Takahara K, Takai T, Uchimoto T, Saito K, Tanda N, et al. 2018. A panel of MicroRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder. Dis Markers. 2018:5468672.
   Web of Science ®Google Scholar
• Kumar AS, Rayala SK, Venkatraman G. 2018. Targeting IGF1R pathway in cancer with microRNAs: how close are we? RNA Biol. 15:320–326.
   PubMed Web of Science ®Google Scholar
• Lazzarini R, Caffarini M, Delli Carpini G, Ciavattini A, Di Primio R, Orciani M. 2020. From 2646 to 15: differentially regulated microRNAs between progenitors from normal myometrium and leiomyoma. Am J Obstet Gynecol. 222:596.e1–596.e9.
   Web of Science ®Google Scholar
• Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. 2016. Economic burden of bladder cancer across the European Union. Eur Urol. 69:438–447.
   PubMed Web of Science ®Google Scholar
• Lou W, Ding B, Xu L, Fan W. 2019. Construction of potential glioblastoma multiforme-related miRNA-mRNA regulatory network. Front Mol Neurosci. 12:66.
   PubMed Web of Science ®Google Scholar
• Lu D, Tang L, Zhuang Y, Zhao P. 2018. miR-17-3P regulates the proliferation and survival of colon cancer cells by targeting Par4. Mol Med Rep. 17:618–623.
   Web of Science ®Google Scholar
• Maki RG. 2010. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol. 28:4985–4995.
   PubMed Web of Science ®Google Scholar
• Motawi TK, Rizk SM, Ibrahim TM, Ibrahim IA-R. 2016. Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis. Cell Biochem Funct. 34:142–148.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. 2010. Edger: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140.
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Yoshino H, Yonemori M, Miyamoto K, Sugita S, Matsushita R, Itesako T, Tatarano S, Nakagawa M, Enokida H. 2018. Erratum: regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. Br J Cancer. 118:e7.
   Web of Science ®Google Scholar
• Shi Z, Kadeer A, Wang M, Wen B, Li M, Huang J, Gao Y, Liu E, Liu D, Jia D, et al. 2019. The deregulation of miR-133b is associated with poor prognosis in bladder cancer. Pathol Res Pract. 215:354–357.
   Web of Science ®Google Scholar
• Stel VS, Dekker FW, Tripepi G, Zoccali C, Jager KJ. 2011. Survival analysis II: cox regression. Nephron Clin Pract. 119:c255–c260.
   PubMedGoogle Scholar
• Sui J, Xu S-Y, Han J, Yang S-R, Li C-Y, Yin L-H, Pu Y-P, Liang G-Y. 2017. Integrated analysis of competing endogenous RNA network revealing lncRNAs as potential prognostic biomarkers in human lung squamous cell carcinoma. Oncotarget. 8:65997–66018.
   PubMedGoogle Scholar
• Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al. 2017. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45:D362–D368.
   PubMed Web of Science ®Google Scholar
• Taheri M, Shirvani-Farsani Z, Ghafouri-Fard S, Omrani MD. 2020. Expression profile of microRNAs in bladder cancer and their application as biomarkers. Biomed Pharmacother. 131:110703.
   Web of Science ®Google Scholar
• Taylor J, Becher E, Steinberg GD. 2020. Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 125:197–205.
   PubMed Web of Science ®Google Scholar
• Xu K, Zhan Y, Yuan Z, Qiu Y, Wang H, Fan G, Wang J, Li W, Cao Y, Shen X, et al. 2019. Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop. Mol Ther. 27:1810–1824.
   PubMed Web of Science ®Google Scholar
• Yin X-H, Jin Y-H, Cao Y, Wong Y, Weng H, Sun C, Deng J-H, Zeng X-T. 2019. Development of a 21-miRNA signature associated with the prognosis of patients with bladder cancer. Front Oncol. 9:729.
   Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, He Q-Y. 2012. Clusterprofiler: an R package for comparing biological themes among gene clusters. OMICS. 16:284–287.
   PubMed Web of Science ®Google Scholar
• Yu N, Yong S, Kim HK, Choi Y, Jung Y, Kim D, Seo J, Lee YE, Baek D, Lee J, et al. 2019. Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor–normal samples in lung adenocarcinoma. Mol Oncol. 13:1356–1368.
   Web of Science ®Google Scholar
• Zhang Y, Zhang D, Lv J, Wang S, Zhang Q. 2018. MiR-125a-5p suppresses bladder cancer progression throughtargeting FUT4. Biomed Pharmacother. 108:1039–1047.
   PubMed Web of Science ®Google Scholar
• Zhou H, Tang K, Xiao H, Zeng J, Guan W, Guo X, Xu H, Ye Z. 2015. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res. 34:53.
   Web of Science ®Google Scholar
• Zhou P, Li X. 2019. Serum miR-338-5p has potential for use as a tumor marker for retinoblastoma. Oncol Lett. 18:307–313.
   Web of Science ®Google Scholar